<DOC>
	<DOCNO>NCT00088114</DOCNO>
	<brief_summary>The purpose study determine safety , toxicity maximum tolerate dose single dos STA-4783/paclitaxel combination administer intravenously patient refractory cancer . To determine pharmacokinetics STA-4783 paclitaxel co-administered . To assess anti-tumor activity STA-4783 paclitaxel co-administered .</brief_summary>
	<brief_title>STA-4783 Paclitaxel Treatment Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male female patient great equal 18 year age histologically confirm malignancy metastatic unresectable standard therapy exists . Patients must receive prior chemotherapy radiation great equal 4 week study enrollment . Patients may enter receive prior radiation therapy involve less equal 30 % bone marrow . Any prior radiation therapy must administer great equal 4 week study enrollment patient must recover acute toxic effect treatment prior study entry . Patients may enrol history treat brain metastasis clinically stable great equal 4 week prior enrollment . ECOG Performance Status less equal 2 . Life expectancy great 12 week . No peripheral neuropathy &gt; grade 1 NCI CTC version 2 scale , history stroke significant neurological limitation determine investigator . Patients must acceptable organ marrow function screen predose visit define . Absolute neutrophil count great equal 1,500/ul Platelets great equal 100,000 cells/ul Total bilirubin must within normal limit AST ( SGOT ) less equal 2.5 time upper limit normal Serum creatinine &lt; 1.5 mg/dl measure creatine clearance great equal 50 mL/min Electrocardiogram without evidence clinically significant conduction abnormality active ischemia determine investigator . The effect STA4783 develop human fetus unknown , however taxanes know teratogenic . Therefore , woman childbearing potential ( defined woman less equal 50 year age history amenorrhea &lt; 12 month prior study entry ) must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Ability understand willingness sign write informed consent document . Women pregnant lactating . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier . Patients previous high dose chemotherapy autologous stem cell rescue bone marrow transplantation . Use investigational agent within 4 week study enrollment . History severe allergic reaction paclitaxel docetaxel include severe hypersensitivity reaction define great equal 3 base NCI CTC version 2 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia psychiatric illness/social situation would limit compliance study requirement , determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>